Although no phase III trials comparing BRAF/MEK inhibitors and standard chemotherapy +/− immunotherapy are available, these data led to the approval of this combination as a first-line-strategy in patients with advanced NSCLC and BRAF mutation [14,15]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.